Baloxavir might offer a new prospect for influenza treatment given its effectiveness and safety profile. 

To assess the safety and efficacy of Baloxavir marboxil tablets in treating influenza A.

Based on a computer-generated random sequence, 200 patients diagnosed with influenza A were randomly divided into two groups, each containing 100 patients.

The study group received oral Baloxavir marboxil tablets at a dose of 40 mg once daily, while the control group received oral Oseltamivir capsules at a dose of 75 mg twice daily for 5 consecutive days. Following the 5-day treatment period, the therapeutic effects, time to symptom disappearance, and occurrence of adverse drug reactions were compared.

There were no notable disparities observed in the overall efficacy rate between the two groups (99% vs. 98%, p > 0.05). Additionally, there were no significant discrepancies found in the duration of fever resolution (1.54 ± 0.66 days vs. 1.67 ± 0.71 days, p > 0.05), cough improvement time (2.26 ± 0.91 days vs. 2.30 ± 0.90 days, p > 0.05), and sore throat improvement time (2.06 ± 0.86 days vs. 2.09 ± 0.83 days, p > 0.05) between the two groups. Moreover, there were no significant variances in the occurrence of adverse drug reactions between the groups.

Baloxavir marboxil tablets demonstrate effective utility in treating influenza A patients and exhibit comparable efficacy and safety to Oseltamivir capsules.